Pancreatic Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pancreatic Cancer stocks.

Pancreatic Cancer Stocks Recent News

Date Stock Title
Nov 21 INCY Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Nov 21 NVCR Novocure secures FDA approval for add-ons to brain cancer treatment wearable
Nov 21 NVCR Novocure gets FDA approval for its HFE transducer arrays for glioblastoma treatment
Nov 21 NVCR Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Nov 21 NVCR FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Nov 20 RNXT Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Nov 20 OPK OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nov 19 EXAS Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now
Nov 19 INCY Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
Nov 19 INCY Equity Markets Close Mixed Ahead of Nvidia Earnings
Nov 19 INCY S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
Nov 19 EXAS Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Nov 19 INCY Sector Update: Health Care Stocks Decline
Nov 19 INCY Top Midday Decliners
Nov 19 INCY Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
Nov 19 INCY Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
Nov 19 INCY Incyte seesaws on report of potential Merck takeover interest
Nov 19 INCY Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
Nov 19 INCY Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
Nov 19 INCY Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Pancreatic Cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. There are a number of types of pancreatic cancer. The most common, pancreatic adenocarcinoma, accounts for about 85% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas which makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the non-adenocarcinomas, can also arise from these cells. One to two percent of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma.Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine and loss of appetite. There are usually no symptoms in the disease's early stages, and symptoms that are specific enough to suggest pancreatic cancer typically do not develop until the disease has reached an advanced stage. By the time of diagnosis, pancreatic cancer has often spread to other parts of the body.Pancreatic cancer rarely occurs before the age of 40, and more than half of cases of pancreatic adenocarcinoma occur in those over 70. Risk factors for pancreatic cancer include tobacco smoking, obesity, diabetes, and certain rare genetic conditions. About 25% of cases are linked to smoking, and 5–10% are linked to inherited genes. Pancreatic cancer is usually diagnosed by a combination of medical imaging techniques such as ultrasound or computed tomography, blood tests, and examination of tissue samples (biopsy). The disease is divided into stages, from early (stage I) to late (stage IV). Screening the general population has not been found to be effective.The risk of developing pancreatic cancer is lower among non-smokers, and people who maintain a healthy weight and limit their consumption of red or processed meat. A smoker's chance of developing the disease decreases if they stop smoking, and almost returns to that of the rest of the population after 20 years. Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy, palliative care, or a combination of these. Treatment options are partly based on the cancer stage. Surgery is the only treatment that can cure pancreatic adenocarcinoma, and may also be done to improve quality of life without the potential for cure. Pain management and medications to improve digestion are sometimes needed. Early palliative care is recommended even for those receiving treatment that aims for a cure.In 2015, pancreatic cancers of all types resulted in 411,600 deaths globally. Pancreatic cancer is the fifth most common cause of death from cancer in the United Kingdom, and the fourth most common in the United States. The disease occurs most often in the developed world, where about 70% of the new cases in 2012 originated. Pancreatic adenocarcinoma typically has a very poor prognosis: after diagnosis, 25% of people survive one year and 5% live for five years. For cancers diagnosed early, the five-year survival rate rises to about 20%. Neuroendocrine cancers have better outcomes; at five years from diagnosis, 65% of those diagnosed are living, though survival varies considerably depending on the type of tumor.

Browse All Tags